debulking surgery . J Surg Oncol 1991 ; 48 : 39 – 44 . 4. McGuire WP Hoskins WJ Brady MF . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996
Search Results
The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer
Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim
Edited by Kerrin G. Robinson
Access to and Appropriateness of Cancer Care: Who Decides?
William T. McGivney
paclitaxel in combination be a treatment option for women with metastatic breast cancer. The vote of the NCCN Guidelines Panel on this issue was 15 to 0. The European Medicines Agency, the counterpart of the FDA for the European Union, has adopted a position
NCCN Guidelines Updates: Breast Cancer
Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar
single standard treatment exists for patients with small, node-negative, HER2-positive breast cancers, but there is evidence that chemotherapy might be useful in some. Tolaney et al 3 conducted a study of adjuvant paclitaxel (given weekly for 12 weeks
Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
weekly paclitaxel, 2 single-arm phase II trials evaluated the utility of short-course docetaxel/cyclophosphamide (DCH for 4 cycles) 13 or paclitaxel (weekly for 12 weeks) 14 in combination with trastuzumab for low-risk HER2+ breast cancer. Both trials
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer
Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J. Vlachostergios, Brian D. Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S. Scherr, Andrea Sboner, Scott T. Tagawa, Ana M. Molina, Olivier Elemento, David M. Nanus, and Bishoy M. Faltas
treated with trastuzumab, paclitaxel, carboplatin, and gemcitabine, 14 ERBB2 overexpression by IHC, gene amplification in the tumor by FISH, or presence in serum for extracellular ERBB2 domain testing by quantitative enzyme-linked immunosorbent assay was
Carcinosarcomas (Malignant Mixed Müllerian Tumor) of the Uterus: Advances in Elucidation of Biologic and Clinical Characteristics
Lauren E. Kernochan and Rochelle L. Garcia
Edited by Kerrin G. Robinson
chemotherapy regimens containing platinum . Gynecol Oncol 2008 ; 108 : 136 – 140 . 28 Homesley HD Filiaci V Markman M . Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancer
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
randomized phase III ECOG 4599 trial, which demonstrated an OS advantage associated with addition of bevacizumab to carboplatin/paclitaxel. 11 Although results of the PointBreak trial showed that carboplatin/pemetrexed/bevacizumab yielded similar OS compared
Oncology Research Program
Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously over 30 minutes and carboplatin intravenously over 1 to 2 hours on day 1. Treatment repeats
NCCN Guidelines® Updates
preoperative neoadjuvant paclitaxel, ifosfamide, and cisplatin ( TIP ). Stable or responding patients should then undergo surgical resection consolidative surgery ...” For “Preferred radiosensitizing agents and combinations,” the heading was clarified
NCCN News
addition of bevacizumab to upfront therapy with carboplatin/paclitaxel or as maintenance therapy at this time. The NCCN panel encourages participation in ongoing clinical trials that are further investigating the role of antiangiogenesis agents in the
